Skip to main content

Clinical trial A-48-52030-269 IMIO

An International, Multicentric, prospective, open LaBEL study to assess the efficacy and safety of Lanreotide Autogel 120 mg associated to standard of care in the treatment of clinical symptoms associated with inoperable malignant intestinal obstruction (IMIO)

Organ all types
Trial status Trial closed for recruitment
Trial type
Prospective interventional
Phase Trial phase 2
Academic trial Non
Sponsor Ipsen
EudraCT Identifier 2013-002174-43
Last update